FIGURE 1.

Casodex disrupts telomeric complexes in AR-positive prostate cancer cells. A and B, LNCaP cells treated with 100 μm Casodex for 48 h (A and B) or with 20 μg/ml etoposide for 1 h (B) were co-immunostained with antibodies against 53BP1 and TRF2. LNCaP (C) or PC-3 (D) cells were treated with or without 100 μm Casodex for 48 h and then immunostained with 53BP1 antibody. 53BP1 foci were counted, and data are presented as the percentage of cells with 0–5, 6–10, 11–20, or >20 foci/cell. Immunostaining and confocal microscopy were performed as described under “Experimental Procedures.” 80 cells in each treatment group were scored in three separate experiments.